Biotech News

Apyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with Liposuction

Apyx Medical (APYX)Apyx MedicalFDA / regulatory

Analysis showed that liposuction followed by helium plasma RF was associated with higher patient-reported satisfaction with abdominal appearance, lower abdominoplasty and revision rates, and comparable complication rates versus conventional liposuction alone

May 14, 2026 08:00 ET | Source: Apyx Medical Corporation

CLEARWATER, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion ® and the AYON Body Contouring System™ (AYON), today announced the publication of a new retrospective investigator-initiated study in Plastic and Reconstructive Surgery - Global Open 1 . The study evaluated patient-reported outcomes following liposuction with and without helium plasma radiofrequency (Renuvion).

The results demonstrate that adding Renuvion to liposuction resulted in statistically significant improvements in patient-reported satisfaction with abdominal appearance and excess skin, along with lower rates of abdominoplasty and surgical revisions, while maintaining comparable complication rates to power-assisted liposuction.

Key Findings from the 113‑Patient Study

Patients treated with Renuvion reported statistically higher satisfaction with reduced appearance of excess skin (Body‑Q score 87.8 vs. 73.8; p=0.03)

Among patients who did not undergo abdominoplasty, satisfaction with abdominal appearance was also statistically higher (68.8 vs. 45.0; p=0.039)

The rate of patients requiring abdominoplasty was more than 50% lower in the Renuvion group compared to the group receiving power-assisted liposuction only (30.0% vs. 67.1%)

Revision rates were significantly lower in the Renuvion group (12.0% vs. 37.5%; p=0.038)

Complication rates remained similar between groups (2.5% vs. 2.7%)

“This study adds to the growing body of clinical evidence supporting the use of Renuvion in aesthetic body contouring,” said Charlie Goodwin, President and Chief Executive Officer of Apyx Medical. “With more than 2 million liposuction procedures performed globally each year*, these statistically significant improvements in patient satisfaction and reduced revision rates underscore the value Renuvion provides to aesthetic surgeons and their patients.”

The retrospective study, led by Pablo D. Huber, MD, evaluated long-term (>12 month) Body-Q® patient-reported outcomes, procedural data, and safety profiles across 113 patients treated by a single surgeon. The Renuvion cohort (power-assisted liposuction + Renuvion) consistently reported higher satisfaction with skin quality and abdominal contour, with no increase in complications.

Apyx Medical’s latest technology, the AYON Body Contouring System™, builds on the proven foundation and technology of Renuvion, leveraging decades of clinical evidence and real-world experience to deliver precise, efficient, and effective energy-based solutions in an all-in-one system.

1 A digital version of the clinical publication is available via the following link: Plastic and Reconstructive Surgery – Global Open.

*Source: ISAPs 2024 Survey

About AYON Body Contouring System™: AYON is a groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates advanced fat removal technologies, Renuvion’s tissue contraction and electrosurgical capabilities, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. With advanced features like LIFT Technology for real-time adjustments and Renuvion for enhanced tissue contraction, AYON sets a new standard in surgical care, streamlining procedures and maximizing patient outcomes. Backed by Apyx Medical’s expertise and evidence-based design, AYON delivers consistent, reliable performance and an unmatched return on investment. As the first of its kind, AYON is revolutionizing body contouring and shaping the future of aesthetic surgery.

Apyx Medical Corporation : Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion and the AYON Body Contouring System™ in the cosmetic surgery market and J-Plasma ® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com .

Investor Relations Contact: Jeremy Feffer Managing Director LifeSci Advisors OP: 212-915-2568 [email protected]

Related news

APYXApyx Medical2026-05-11 12:00 EST

Apyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System™

ICCMIceCure Medical2026-07-29 12:25 EST

IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®

ICCMIceCure Medical2026-07-06 12:11 EST

IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer

HYPRHyperfine2026-05-26 12:15 EST

Hyperfine to Join Russell 2000® and Russell 3000® Indexes

APYXApyx Medical2026-05-21 12:00 EST

New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli® and Renuvion®

FEMYFEMASYS2026-05-13 13:00 EST

Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter

PRCTPROCEPT BioRobotics2026-05-28 12:00 EST

PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval

AEMDAethlon Medical2026-07-13 12:01 EST

Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®

CVRXCVRx2026-05-04 20:30 EST

CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

AEMDAethlon Medical2026-06-26 12:01 EST

Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®

Apyx Medical

Apyx Medical is a medical device company focused on energy-based surgical products and dermatologic procedures. Its business is tied to procedure demand and device adoption.

Recent company news

Stock data

Close
3.86 USD
Market cap
161.21M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States